Akèy › Timè nan sèvo
Etid klinik pou Timè nan sèvo ap rekrite nan Etazini
198 etid pou Timè nan sèvo ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX35 etid
- Boston, MA28 etid
- New York City, NY25 etid
- Washington, DC20 etid
- Los Angeles, CA16 etid
- Miami, FL15 etid
- Durham, NC14 etid
- St. Louis, MO12 etid
- Rochester, MN12 etid
- Columbus, OH11 etid
- Baltimore, MD11 etid
- Chicago, IL11 etid
- Cleveland, OH11 etid
- Seattle, WA11 etid
- Ann Arbor, MI10 etid
- Atlanta, GA9 etid
- Aurora, CO9 etid
- Detroit, MI9 etid
- Dallas, TX8 etid
- Arlington, VA8 etid
- Portland, OR8 etid
- San Francisco, CA8 etid
- Minneapolis, MN8 etid
- Nashville, TN8 etid
- San Antonio, TX7 etid
- Jacksonville, FL7 etid
- Baldwin Park, CA7 etid
- Mountain View, CA7 etid
- Salt Lake City, UT7 etid
- Cincinnati, OH7 etid
- San Diego, CA7 etid
- Philadelphia, PA7 etid
- Tampa, FL6 etid
- Madison, WI5 etid
- Birmingham, AL5 etid
- Winston-Salem, NC5 etid
- Milwaukee, WI5 etid
- Scottsdale, AZ5 etid
- New Rochelle, NY4 etid
- Gainesville, FL4 etid
Pa eta
- Alabama5 etid
- Arizona11 etid
- Arkansas3 etid
- Colorado11 etid
- Distrik Columbia13 etid
- Florid29 etid
- Georgia12 etid
- Idaho3 etid
- Illinois14 etid
- Indiana4 etid
- Iowa4 etid
- Kalifòni39 etid
- Kansas3 etid
- Kentucky5 etid
- Maryland18 etid
- Massachusetts29 etid
- Michigan19 etid
- Minnesota19 etid
- Missouri13 etid
- Montana3 etid
- Nebraska5 etid
- New Hampshire4 etid
- New Jersey8 etid
- New York35 etid
- North Carolina20 etid
- Ohio23 etid
- Oklahoma3 etid
- Oregon8 etid
- Pennsylvania13 etid
- Rhode Island3 etid
- South Carolina5 etid
- Tennessee12 etid
- Texas42 etid
- Utah8 etid
- Virginia15 etid
- Washington12 etid
- Wisconsin11 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Ap rekriteFaz 1
Laj 21 a 70 · Tout sèks · Mizajou Sep 30, 2026 · NCT06815432Evaluation and Treatment of Neurosurgical Disorders
Ap rekriteEtid obsèvasyon
Laj 4 a 99 · Tout sèks · Mizajou Sep 29, 2026 · NCT00060541Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 29, 2026 · NCT04085887Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Sep 28, 2026 · NCT07416188SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04923542Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07326566C-SMART vs BE Well for Patients With Brain Tumors
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07224503Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT06389591Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05733312Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07470606Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07248228Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT04977375REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07831772Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
Ap rekriteFaz 1 bonè
Laj 18 a 99 · Tout sèks · Mizajou Sep 21, 2026 · NCT06055790Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07053033A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05048212PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07827001Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07227610Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07492680OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07655583A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04511013Development of MRF for Characterization of Brain Tumors After Radiotherapy
Ap rekriteVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Sep 15, 2026 · NCT06101069Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Ap rekriteFaz 2
59 Months · Tout sèks · Mizajou Sep 15, 2026 · NCT05535166Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.